A collaborative effort between investigators at the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding ...

A collaborative effort between investigators at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding ...

The development of new adenine base editors (ABE) and adenine-to-thymine/guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and ...

New gene editing techniques, like adenine base editing and prime editing, are creating new possibilities for treating dilated cardiomyopathy, a heart condition affecting about 1 in 250 people ...

Combination of Revvity’s proprietary Pin-point platform and Profluent’s AI-engineered proteins created to inspire accelerated development of novel gene editing therapies This new Pin-point ...

Cytosine and adenine base editors (CBEs and ABEs) are promising new tools for achieving the precise genetic changes required for disease treatment and trait improvement. However, genome-wide and ...

X-linked chronic granulomatous disease (X-CGD) is a rare genetic disorder characterized by high susceptibility to infections that results from genetic mutations in the cytochrome b-245 beta chain ...

Metagenomi Adenine Base Editors (ABEs) demonstrated over 95% genome targetability Simultaneous ABE triplex editing resulted in over 95% protein knockdown in primary T-cells ABE demonstrated highly ...

Adenine was first discovered in 1885 by the German physiologist Albrecht Kossel. He isolated adenine from the pancreas of oxen and named it "adenine" derived from the Greek word "aden," meaning gland.

A collaboration between scientists at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) and Beam Therapeutics has resulted in a new base editing therapy for Stargardt disease, the most ...